Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Capsule Clear all
Withdrawn Phase 1 Interventional

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

NCT03414450
View directory record Official record
Conditions
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Ph- Acute Lymphoblastic Leukemia (Ph-ALL), Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+), Chronic Myeloid Leukemia Blast Crisis (CML-BC, Ph+)
Interventions
ETC-1907206, dasatinib
Drug
Lead sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Government
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Bethesda, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

NCT04375813
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
eRapa, Placebos
Drug
Lead sponsor
Robert Svatek
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 10, 2026, 11:34 PM EDT
Withdrawn Phase 2 Interventional

Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence

NCT03566290
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
GTx-024
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
46
States / cities
Homewood, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Sep 10, 2026, 11:34 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence

NCT01480232
View directory record Official record
Conditions
Nicotine Dependence, Smoking Cessation
Interventions
EVP-6124, Placebo Capsule, NicoDerm Patch (Active), NRT Patch (Placebo), Brief Supportive and Behavioral Treatment
Drug · Behavioral
Lead sponsor
A. Eden Evins
Other
Eligibility
18 Years to 65 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 10, 2026, 11:34 PM EDT
Recruiting Not applicable Interventional

Concentration of n-3 PUFA Monohydroxylated Derivatives in Adults With Obesity After n-3 PUFA Supplementation.

NCT06991296
View directory record Official record
Conditions
Obesity
Interventions
SPM Active®
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 1 Interventional

Omega-3 and Therapy Study for Depression

NCT01341925
View directory record Official record
Conditions
Depression
Interventions
Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo
Drug · Behavioral · Other
Lead sponsor
L. Eugene Arnold
Other
Eligibility
7 Years to 14 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

NCT00758524
View directory record Official record
Conditions
Essential Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 10, 2026, 11:34 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

NCT03800420
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S first and then Placebo, Placebo first and then BBT-401-1S
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Sacramento, California • Ventura, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 10, 2026, 11:34 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Trenev Trio®/Healthy Trinity® for Recurrent Gastrointestinal Symptoms

NCT01444859
View directory record Official record
Conditions
Recurrent Gastrointestinal Symptoms
Interventions
Trenev Trio®/Healthy Trinity®, Placebo
Dietary Supplement
Lead sponsor
Sprim Advanced Life Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • West Lawn, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

NCT04717726
View directory record Official record
Conditions
Obesity
Interventions
Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON)
Dietary Supplement · Behavioral
Lead sponsor
Kyle Flack
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera

NCT03705585
View directory record Official record
Conditions
Typhoid and/or Cholera Vaccination
Interventions
Vivotif Typhoid Oral Vaccine, Vaxchora
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2Phase 3 Interventional

A Trial of Metformin in Individuals With Fragile X Syndrome

NCT03479476
View directory record Official record
Conditions
Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders
Interventions
Placebo Medication, Metformin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years to 25 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Early Phase 1 Interventional Results available

Ginger's Therapeutic Potential in Asthma

NCT03705832
View directory record Official record
Conditions
Asthma
Interventions
Ginger Extract, Placebo
Drug
Lead sponsor
Emily DiMango, MD
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of Corticosteroid Induced Hippocampal Changes

NCT01656187
View directory record Official record
Conditions
Organic Memory Impairment
Interventions
Memantine 10 mg capsule, Memantine-matched Placebo capsule
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.

NCT01166425
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Washington D.C., District of Columbia • South Chicago Heights, Illinois • Psychiatry and Behavioral Sciences, 1010 N Kansas St, Wichita, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

Effect of Galantamine on Short-term Abstinence

NCT01669538
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

NCT00251693
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Lansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
2,038 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
96
States / cities
Alabaster, Alabama • Birmingham, Alabama • Huntsville, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 10, 2026, 11:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

NCT07046806
View directory record Official record
Conditions
Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
Interventions
Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule, Placebo comparator to 20 mg capsule
Drug
Lead sponsor
Institute for Asthma and Allergy
Network
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

NCT04429555
View directory record Official record
Conditions
Pneumonia, Viral
Interventions
Ibudilast, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Denver, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Health1: A Study of Health and Wellness Formulations and Their Effects on Overall Health

NCT05783232
View directory record Official record
Conditions
Sleep, Pain, Depression, Anxiety
Interventions
Placebo Control Form 1 Capsules, Health Active Study Product 1.1 Capsules, Health Active Study Product 1.2 Capsules, Health Active Study Product 1.3 Capsules
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health

NCT04001088
View directory record Official record
Conditions
Menopause
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Lallemand Health Solutions
Industry
Eligibility
40 Years to 59 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Lake Worth, Florida • Port Saint Lucie, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

NCT01566773
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Sep 10, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

NCT02706873
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 10, 2026, 11:34 PM EDT